Non-alcoholic steatohepatitis: Definitions and pathogenesis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue SUPPL. 3, 2002, Pages

  Day, C P ^a   Saksena, S ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOTOXIN; FATTY ACID; INSULIN; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOL LIVER CIRRHOSIS; CONFERENCE PAPER; CYTOKINE RELEASE; DISEASE MODEL; DISEASE PREDISPOSITION; HUMAN; IMMUNITY; INSULIN RESISTANCE; LIVER CELL DAMAGE; LIVER DISEASE; NON ALCOHOLIC STEATOHEPATITIS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; STEATOSIS;

EID: 0036454882     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.17.s3.31.x     Document Type: Conference Paper

References (62)

1. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980; 55: 434-8.
2. James OFW, Day CP. Non-alcoholic steatohepatitis (NASH): A disease of emerging identity and importance. J. Hepatol. 1998; 29: 495-501.
3. Brunt EM, Janney CG, Di Bisceglie AM et al. Non-alcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94: 2467-74.
4. Byron D, Minuk GY. Profile of an urban hospital-based practice. Hepatology 1996; 24: 813-15.
5. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J. Hepatol. 2001; 35: 195-9.
6. Marchesini G, Brizi M, Bianchi G et al. Non-alcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
7. Ferrannini. Insulin resistance, iron and the liver. Lancet 2000; 255: 2181-2.
8. Matteoni CA, Younossi ZM, Gramlich T et al. Non-alcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-19.
9. Caldwell SH, Oelsner DH, Lezzoni JC et al. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-70.
10. Poonwala A, Nair S, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study. Hepatology 2000; 32: 689-92.
11. Day CP, James OFW. Steatohepatitis: A tale of two 'hits'? Gastroenterology 1998; 114: 842-5.
12. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
13. Sorensen TI, Orholm M, Bentsen KD, Hoybye G, Eghoje K, Christoffersen P. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet 1984; 2: 241-4.
14. Teli MR, Day CP, Burt AD, Bennett MK, James OFW. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 246: 987-90.
15. Adinolfi LE, Gambardella M, Andreana A, Tripodi M-F, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
16. Reeves HL, Burt AD, Wood S, Day CP. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J. Hepatol. 1996; 25: 677-83.
17. Stewart S, Jones D, Day CP. Alcoholic liver disease: New insights into mechanisms and preventative strategies. Trends Mol. Med. 2001; 7: 408-13.
18. Day CP. Apoptosis in alcoholic hepatitis: A novel therapeutic target? J. Hepatol. 2001; 34: 330-3.
19. Parlesak A, Schafer C, Schutz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J. Hepatol. 2000; 32: 742-7.
20. Bird GLA, Sheron N, Goka AKJ, Alexander GJ, Williams RS. Increased plasma tumour necrosis factor in severe alcoholic hepatitis. Ann. Intern. Med. 1990; 112: 917-20.
21. Mottaran E, Stewart SF, Rolla Ret al. Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Free Radic. Biol. Med. 2001; 32: 38-45.
22. Lytton S, Helander A, Zhang-Guillon Z, et al. Antibodies against cytochromes P-4502E1 and P-4503A in alcoholics. Mol. Pharmacol. 1999; 55: 223-33.
23. Clot P, Parola M, Bellomo G, et al. Plasma membrane hydroxyethyl radical adducts cause antibody-dependent cytotoxicity in rat hepatocytes exposed to alcohol. Gastroenterology 1997; 113: 265-76.
24. George DK, Goldwurm S, Macdonald GA et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis.Gastroenterology 1998; 114: 311-18.
25. Leclerq IA, Farrell GC, Field J et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatatis. J. Clin. Invest. 2000; 105: 1067-75.
26. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Non-alcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
27. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass. Prevention and reversal by metronidazole irrespective or protein-calorie malnutrition. Gastroenterology 1982; 83: 534-48.
28. Wigg AJ, Roberts-Thomson IC, Dymock RB et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factora in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-11.
29. Yang SQ, Lin HZ, Lane MD et al. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis. Proc. Natl Acad. Sci. USA 1997; 94: 2557-62.
30. Day C. CD14 promoter polymorphism associated with risk of NASH. J. Hepatol. 2002; 36 (Suppl.): 21.
31. Crespo J, Cayon A, Fernandez-Gil P et al. Gene expression of tumour necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-63.
32. Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J. Hepatol. 1996; 24: 200-8.
33. Letteron P, Duchatelle V, Berson A et al. Increased ethane exhalation, an in vivo index of lipid peroxidation in alcohol abusers. Gut 1993; 34: 409-14.
34. Guebre-Xabier M, Yang S, Lin HZ, Schwenk R, Krych U, Diehl AM. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: Potential mechanism for sensitisation to liver damage. Hepatology 2000; 31: 633-40.
35. Chavin KD, Yang SQ, Lin HZ et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J. Biol. Chem. 1999; 274: 5692-700.
36. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis. A pilot study. J. Am. Med. Assoc. 1999; 282: 1659-64.
37. Hui AM, Kawasaki S, Makuuchi Met al. Liver injury following normothermic ischemia in steatotic rat liver. Hepatology 1994; 20: 1287-93.
38. Yang SQ, Lin HZ, Mandal AK, Huang J, Diehl AM. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: Implications for nonalcoholic fatty liver disease pathophysiology. Hepatology 2001; 34: 694-706.
39. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: Implications for human obesity. Proc. Natl. Acad. Sci. USA 2000; 97: 1784-9.
40. Ruderman NB, Saha AK, Vavvas D, Witters LA. Malonyl-CoA, fuel sensing, and insulin resistance. Am. J. Physiol. 1999; 276: E1-18.
41. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput J-C. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25: 108-11.
42. Angulo P, Keach JC, Batts KP et al. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
43. Ratziu V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients.Gastroenterology 2000; 118: 1117-23.
44. Dixon JB, Bhathal PS, O'Brian PE. Non-alcoholic fatty liver disease: Predictors of non-alcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
45. Bjorntorp P, Bergman H, Varnauskas E. Plasma free fatty acid turnover in obesity. Acta Med. Scand. 1969; 185: 351-6.
46. Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM. Influence of body fat distribution on free fatty acid metabolism in obesity. J. Clin. Invest. 1989; 83: 1168-73.
47. Arner P. Not all fat is alike. Lancet 1998; 351: 1301-2.
48. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet 2002; 359: 46-7.
49. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect 'cushing's disease of the omentum'? Lancet 1997; 349: 1210-13.
50. Kim JK, Kim Y-J, Fillmore JJ et al. Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest. 2001; 108: 437-46.
51. Yuan M, Konstantopoulos N, Lee J et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKβ. Science 2001; 293: 1673-7.
52. Birnbaum MJ. Turning down insulin signaling. J. Clin. Invest. 2001; 108: 655-9.
53. Clarke SD. Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am. J. Physiol. 2001; 281: G865-9.
54. Shulman GI. Cellular mechanisms of insulin resistance. J. Clin. Invest. 2000; 106: 171-6.
55. Minokoshi Y, Kim Y-B, Peroni OD et al. Leptin stimulates fatty acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415: 339-43.
56. Lee Y, Wang MY, Kakuma T et al. Liporegulation in diet-induced obesity: The antisteatotic role of hyperleptinemia. J. Biol. Chem. 2001; 276: 5629-35.
57. Woodcroft KJ, Hafner MS, Novak R. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology 2002; 35: 263-73.
58. Reddy JK. Nonalcoholic steatosis and steatohepatitis III. Peroxisomal β-peroxidation, PPARα, and steatohepatitis. Am. J. Physiol. 2001; 281: G1333-9.
59. Lancaster JR, Laster SM, Gooding LR. Inhibition of target cell mitochondrial electron transfer by tumour necrosis factor. FEBS Lett. 1989; 248: 169-74.
60. Fan C-Y, Usuda N, Yeldandi AV et al. Steatohepatitis, spontaneous peroxisome proliferation and liver tumours in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J. Biol. Chem. 1998; 273: 15639-45.
61. Cortez-Pinto H, Lin HZ, Yang SQ, Da Costa SOD. Lipids up-regulate uncoupling protein 2 expression in rat hepatocytes. Gastroenterology 1999; 116: 1184-93.
62. Valenti L, Fracanzani AL, Dongiovanni P et al. Tumour necrosis factor a promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-80.